GLP-1 vs Contrave: Which Weight Loss Medication Is More Effective?

What Is Contrave and How Does It Work?

Contrave is a combination prescription medication containing two existing drugs: naltrexone (16mg) and bupropion (360mg) in extended-release formulation. Each component has been available separately for decades — naltrexone for opioid use disorder and alcohol dependence, and bupropion as an antidepressant and smoking cessation aid. The combination was FDA-approved for chronic weight management in adults with BMI ≥30, or ≥27 with weight-related comorbidities, in 2014.

Contrave's mechanism centers on the brain's reward and appetite circuits. Bupropion activates POMC neurons in the hypothalamus — neurons that suppress appetite when activated. However, these POMC neurons also release beta-endorphin, an opioid that normally feeds back to inhibit the neurons' own activity (reducing the appetite-suppressing signal over time). Naltrexone blocks this opioid feedback loop, allowing the POMC neuron activation to be sustained. The combination also acts on dopamine and norepinephrine pathways to reduce food reward signaling.

This mechanism is specifically relevant for "reward-driven eating" — the pattern of eating for pleasure, stress relief, or emotional regulation rather than hunger. Patients who struggle specifically with compulsive eating, emotional eating, or food cravings may find Contrave particularly helpful for addressing these behavioral drivers.

How GLP-1 Medications Work

GLP-1 receptor agonists like semaglutide and tirzepatide take a different approach. Rather than modulating reward circuits, they mimic the GLP-1 hormone produced naturally after eating, directly suppressing appetite through hypothalamic and brainstem GLP-1 receptors. The result is profound appetite suppression — not just reduced cravings, but a fundamental reduction in hunger, food preoccupation, and caloric drive.

GLP-1 medications also slow gastric emptying, promoting physical fullness after smaller meals, and improve insulin secretion and glucose control. Tirzepatide, a dual GLP-1/GIP agonist, adds the appetite-suppressing effects of GIP receptor activation to deliver results that exceed semaglutide alone in clinical trials.

Weight Loss: Head-to-Head Data

The difference in weight loss outcomes is clinically significant. Contrave produces results that are generally consistent with other older-generation weight loss medications — modest but real. GLP-1 medications produce results that are dramatically superior: semaglutide's 15–17% average weight loss places it in ranges previously seen only with bariatric surgery. Tirzepatide's 20–22% average further extends this advantage.

Notably, Contrave's cardiovascular outcomes trial (LIGHT) was halted early due to concerns about meeting its primary endpoints, and interim data showed neutral cardiovascular effects. Semaglutide's SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events — a fundamentally different level of evidence for cardiovascular safety and benefit.

Side Effects and Safety Profiles

GLP-1 medications do not carry neuropsychiatric black box warnings. Their primary side effects are gastrointestinal — nausea, vomiting, and diarrhea that are most prominent during dose escalation and typically improve within 4–8 weeks for most patients. GLP-1 medications also do not block opioid analgesia, making them compatible with patients who may need pain management.

For patients on opioid medications — whether for pain management or addiction treatment — Contrave is simply not usable. The naltrexone component would block opioid effects and could precipitate withdrawal. GLP-1 has no such contraindication.

When Contrave May Have a Specific Role

Despite being outperformed by GLP-1 on most metrics, Contrave has a niche where it may offer specific advantages. Its mechanism targeting reward-driven eating and food cravings makes it potentially useful for patients whose primary weight loss challenge is compulsive or emotional eating rather than general hunger.

Some clinicians also note that bupropion's antidepressant properties can be beneficial for patients with comorbid depression, where appetite reduction and mood improvement occur simultaneously. Patients in smoking cessation (another approved use of bupropion) who are also seeking weight management may find Contrave addresses both goals.

Additionally, for patients with a prior history of opioid use disorder who are no longer on medication-assisted treatment, naltrexone may provide additional benefits for relapse prevention alongside weight management — making Contrave a two-for-one consideration in that specific population.

Cost Analysis

Generic naltrexone/bupropion ER (the generic for Contrave) is now available and priced at $50–$150/month depending on pharmacy. This is lower than compounded GLP-1 from Trimi ($99/month for semaglutide). However, the cost-per-pound-lost calculation strongly favors GLP-1. If Contrave produces 12 pounds of loss and semaglutide produces 35 pounds, the value per pound lost is dramatically different even when monthly costs are similar.

For patients with insurance coverage, either medication may have different out-of-pocket costs depending on formulary placement. It is worth checking with your insurer whether GLP-1 medications are covered under your plan — some insurers cover FDA-approved semaglutide (Wegovy) for qualifying patients. Compounded GLP-1 is typically not covered by insurance but remains affordable through providers like Trimi. See our guide to affordable weight loss program options.

Decision Framework

Frequently Asked Questions